It's not infected sweat glands, and it's not about hygiene. Hair follicles in fold-skin plug up and rupture; the body attacks what spills out. Two signals drive it: TNF and the IL-17 family 1. The cleanest patient still flares. What makes it a race is what rupture does over time: two nearby lesions connect into a draining tract lined with skin cells. Medicine can quiet that tunnel but can't close it.
The medicines each block one of those signals, and they work. Adalimumab (anti-TNF), secukinumab and bimekizumab (anti-IL-17) each get roughly 40 to 60 percent of patients to a real response by week 12 to 16, with pain dropping alongside 2 3. On bimekizumab, the share calling their skin pain "severe" fell from about 30 percent to about 5 percent by a year 4. Response is judged at week 16, not week 4 โ and doses run higher than the psoriasis doses on the same label.
This is a clinician's ladder, not a self-prescribe. Know the shape so you can ask for the right rung.
What treatment buys back. Weeks one to four, little visible. By week eight, fewer flares. By week 16, about half hit a real drop in lesions and pain 4. Within months the daily wound care, the sleep lost to tender spots, and the quiet social withdrawal come off the books together. Old tunnels stay scarred but stop draining and stop hurting.
The fine print โ when to skip it, and what people get wrong
It usually doesn't burn out. The reassurance that HS "goes away in your forties" is mostly wrong; most patients stay active into their fifties. Waiting loses ground you can't get back. Endless antibiotics aimed at "infection" chase the wrong model.
Before any biologic, expect screening for latent TB and hepatitis B and C; no live vaccines while on it. Anti-TNF is avoided in advanced heart failure; anti-IL-17 in active Crohn's or colitis. On rifampicin, hormonal contraception fails โ use a backup through the course and a month after.
The disease is systemic, so screening for depression and cardiovascular risk belongs in routine care 5. Repeating drain-and-repeat surgery without disease-modifying therapy feels productive but doesn't change the trajectory.
- 1Sabat R, Jemec GBE, Matusiak ล, Kimball AB, Prens E, Wolk K (2020). Hidradenitis suppurativa. Nature Reviews Disease Primers. link
- 2Kimball AB, Okun MM, Williams DA, et al. (2016). Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. New England Journal of Medicine. link
- 3Kimball AB, Jemec GBE, Alavi A, et al. (2023). Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. The Lancet. link
- 4Kimball AB, Jemec GBE, Sayed CJ, et al. (2024). Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. The Lancet. link
- 5Egeberg A, Gislason GH, Hansen PR (2016). Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatology. link
Related in the handbook (5)
- โ Smoking is one of the strongest drivers of this disease โ quitting is part of the treatment.
- โ For the depression that rides along with painful chronic disease like HS, exercise is a real lever.
- โ The same TNF biologics treat both conditions, and HS shows up more often in people with Crohn's โ they share inflammatory wiring.
- โ HS travels with insulin resistance and PCOS โ the same hormonal, follicle-clogging biology. Worth screening for if your cycles are off too.
- โ The injectable medicines that changed this disease are part of the same biologic revolution against inflammation.